Abstract 411P
Background
For patients with colorectal liver metastasis (CRLM) who underwent radical resection, the recurrence rate was greater than 50%. Transarterial chemoembolization with drug-eluting beads (DEB-TACE), as a new technique, could improve the response rate and disease-free survival (DFS) in patients with liver-dominant disease. But there is still no study focused on DEB-TACE in preventing postoperative recurrence in patients with CRLM. The aim of this study was to evaluate the efficacy and safety of preoperative DEB-TACE on preventing postoperative recurrence of patients who underwent liver resection.
Methods
This retrospective cohort analysis was conducted at Zhongshan Hospital, Fudan University. Patients with unresectable CRLM who received conversion therapy and converted to R0 resection for liver metastases were collected. When the liver metastases converted to resectable according to multi-disciplinary evaluation, DEB-TACE was performed preoperatively. The primary outcome was DFS and the secondary outcomes were overall survival (OS) and adverse events.
Results
From June 2019 to December 2020, 35 eligible patients were collected. They all had primary tumors resected. 11 (31.4%) patients had RAS mutation. The median number of liver metastases was 7 (Range from 1 to 25) and the median size of the largest liver metastases was 5.1cm (Range from 1.2 to 18.0cm). All patients had clinical risk score (CRS) greater than 3. Most patients (97.1%) converted to resectable during first-line therapy. 21 patients underwent liver resection and intraoperative radiofrequency ablation (RFA) and the remaining 14 patients underwent resection alone. During the median follow-up of 16.2 months, 28 (80.0%) patients had recurrence. The median DFS was 8.3 months. The median OS was not reached. No adverse event > grade 3 by CTCAE was observed during DEB-TACE.
Conclusions
For patients with CRLM, especially patients with high CRS, preoperative DEB-TACE was safe and brought an 8.3 months DFS. Further studies need to be conducted to evaluate whether DEB-TACE could prevent postoperative recurrence and prolong the survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.